Published in JAMA on February 11, 1998
Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. CMAJ (1999) 7.05
Churg-Strauss syndrome. Thorax (2000) 1.27
Eosinophilic pneumonias. Clin Microbiol Rev (2012) 1.20
Eosinophilic esophagitis. World J Gastroenterol (2009) 1.09
Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev (2012) 1.03
Churg-Strauss syndrome (CSS) in a patient receiving pranlukast. Clin Rheumatol (2003) 0.93
Zafirlukast and Churg-Strauss syndrome. JAMA (1998) 0.92
Antileukotriene agents in asthma: the dart that kills the elephant? CMAJ (1999) 0.91
Retracted Increased serum high mobility group box-1 level in Churg-Strauss syndrome. Clin Exp Immunol (2007) 0.89
Difficult asthma or Churg-Strauss syndrome? BMJ (1999) 0.86
Fulminant eosinophilic endomyocarditis in an asthmatic patient treated with pranlukast after corticosteroid withdrawal. Heart (2001) 0.85
Zafirlukast and Churg-Strauss syndrome. JAMA (1998) 0.85
Systemic vasculitis: epidemiology, classification and environmental factors. Ann Rheum Dis (2000) 0.85
Eosinophilic oesophagitis: treatment using Montelukast. Gut (2003) 0.84
Churg-Strauss syndrome associated with leukotriene receptor antagonists. Ulster Med J (2001) 0.80
Churg-Strauss syndrome associated with leukotriene receptor antagonists (LTRA). Clin Rheumatol (2007) 0.78
The linkage between Churg-Strauss syndrome and leukotriene receptor antagonists: fact or fiction? Ther Clin Risk Manag (2005) 0.76
Achieving symptom control in patients with moderate asthma. Clin Med Insights Circ Respir Pulm Med (2011) 0.75
Anti-leukotrienes in Childhood Asthma. Med J Armed Forces India (2011) 0.75
Pulmonary Eosinophilia Following Infliximab Treatment for Crohn's Disease. Gastroenterol Hepatol (N Y) (2006) 0.75
Zafirlukast and Churg-Strauss syndrome. JAMA (1998) 0.75
Churg-Strauss syndrome and the leukotriene receptor antagonist pranlukast. Clin Rheumatol (2004) 0.75
Eosinophilic tumor in a patient with bronchial asthma receiving pranlukast. Eur J Pediatr (2006) 0.75
Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J (2008) 10.08
Sponsorship, authorship, and accountability. Lancet (2001) 7.10
Sponsorship, authorship, and accountability. N Engl J Med (2001) 6.20
Sponsorship, authorship and accountability. CMAJ (2001) 5.86
Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest (2000) 3.84
Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med (1998) 3.83
Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA (2001) 3.21
Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A (1980) 3.18
Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med (1994) 3.09
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med (2000) 3.08
Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A (1980) 2.94
The usefulness of induced sputum in the diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Am Rev Respir Dis (1986) 2.92
The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med (1994) 2.90
Sponsorship, authorship, and accountability. Ann Intern Med (2001) 2.66
Pulmonary responses to bronchoconstrictor agonists in the mouse. J Appl Physiol (1985) (1988) 2.64
Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci U S A (1993) 2.64
Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem Biophys Res Commun (1980) 2.49
Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc Natl Acad Sci U S A (1994) 2.41
Active anaphylaxis in IgE-deficient mice. Nature (1994) 2.32
The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med (1994) 2.23
Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 2.20
The Republican and Democratic candidates speak on health care. N Engl J Med (2000) 2.18
Effects of intravenous administration of slow-reacting substance of anaphylaxis, histamine, bradykinin, and prostaglandin F2alpha on pulmonary mechanics in the guinea pig. J Clin Invest (1974) 2.16
Cytoskeleton of rat aortic smooth muscle cells. Normal conditions and experimental intimal thickening. Lab Invest (1984) 2.15
Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax (2000) 2.10
The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med (1990) 2.03
Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (1994) 2.01
Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J (2000) 1.97
Actin expression in smooth muscle cells of rat aortic intimal thickening, human atheromatous plaque, and cultured rat aortic media. J Clin Invest (1984) 1.95
T-lymphocytes regulate genetically determined airway hyperresponsiveness in mice. Nat Med (1997) 1.94
Bronchoconstrictor effects of leukotriene C in humans. Science (1982) 1.91
To protect those who serve. N Engl J Med (2000) 1.87
Comparative responses of tracheal spirals and parenchymal strips to histamine and carbachol in vitro. J Clin Invest (1978) 1.82
Bronchoalveolar lavage cellularity. The distribution in normal volunteers. Am Rev Respir Dis (1992) 1.81
Penetration of antimicrobial agents into bronchial secretions. Am J Med (1975) 1.74
Surgery for emphysema--not for everyone. N Engl J Med (2001) 1.73
Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med (1995) 1.71
Quantitative locus analysis of airway hyperresponsiveness in A/J and C57BL/6J mice. Nat Genet (1995) 1.70
Effects of leukotriene D on the airways in asthma. N Engl J Med (1983) 1.69
Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J Clin Invest (1997) 1.69
Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest (1997) 1.63
Role of mast cells in anaphylaxis. Evidence for the importance of mast cells in the cardiopulmonary alterations and death induced by anti-IgE in mice. J Clin Invest (1989) 1.62
The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis (1993) 1.62
5' flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol (2000) 1.60
Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study. Am J Respir Crit Care Med (2001) 1.58
Constitutive and allergen-induced expression of eotaxin mRNA in the guinea pig lung. J Exp Med (1995) 1.57
Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Atherosclerosis (1988) 1.57
Characterization of a receptor for C5a anaphylatoxin on human eosinophils. J Biol Chem (1989) 1.49
Beta(2)-adrenoceptor polymorphism and body mass index are associated with adult-onset asthma in sedentary but not active women. Chest (2001) 1.49
Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA (1996) 1.47
Hepatitis C virus infection in kidney transplant recipients. Hepatology (1993) 1.46
Univariate and multivariate family-based association analysis of the IL-13 ARG130GLN polymorphism in the Childhood Asthma Management Program. Genet Epidemiol (2002) 1.46
[Registration of clinical trials: a statement from the International Committee of Medical Journal Editors]. Ned Tijdschr Geneeskd (2004) 1.45
Mechanical stress is communicated between different cell types to elicit matrix remodeling. Proc Natl Acad Sci U S A (2001) 1.45
Cytoskeletal features of rat aortic cells during development. An electron microscopic, immunohistochemical, and biochemical study. Circ Res (1985) 1.43
Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma. Am J Respir Crit Care Med (1999) 1.39
Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? Yes. Am J Respir Crit Care Med (1998) 1.39
Progress at the interface of inflammation and asthma. Report of an ATS-sponsored workshop November, 1993. Am J Respir Crit Care Med (1995) 1.39
Cytoskeletal features of normal and atheromatous human arterial smooth muscle cells. Hum Pathol (1986) 1.39
Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science (1994) 1.38
On the mechanism of mucosal folding in normal and asthmatic airways. J Appl Physiol (1985) (1997) 1.38
Contribution of nitric oxide synthases 1, 2, and 3 to airway hyperresponsiveness and inflammation in a murine model of asthma. J Exp Med (1999) 1.38
Functional characterization of synthetic leukotriene B and its stereochemical isomers. J Exp Med (1981) 1.37
Relaxation of human bronchial smooth muscle by S-nitrosothiols in vitro. J Pharmacol Exp Ther (1994) 1.36
Clinical spectrum of pulmonary mucormycosis. Chest (1986) 1.35
Cloning of DLM-1, a novel gene that is up-regulated in activated macrophages, using RNA differential display. Gene (1999) 1.34
Bronchodilator action of inhaled nitric oxide in guinea pigs. J Clin Invest (1992) 1.34
Evaluation of the substrate specificity of human mast cell tryptase beta I and demonstration of its importance in bacterial infections of the lung. J Biol Chem (2001) 1.34
The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med (1993) 1.32
Differential effects of a partially purified preparation of slow-reacting substance of anaphylaxis on guinea pig tracheal spirals and parenchymal strips. J Clin Invest (1979) 1.32
Leukotriene E4-induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors. Proc Natl Acad Sci U S A (1984) 1.32
Cytodifferentiation and expression of alpha-smooth muscle actin mRNA and protein during primary culture of aortic smooth muscle cells. Correlation with cell density and proliferative state. Arteriosclerosis (1989) 1.32
Transforming growth factor beta 1 modulates extracellular matrix organization and cell-cell junctional complex formation during in vitro angiogenesis. J Cell Physiol (1990) 1.31
In vivo demonstration of nonadrenergic inhibitory innervation of the guinea pig trachea. J Clin Invest (1980) 1.29
Endothelial cell behavior after denudation injury is modulated by transforming growth factor-beta1 and fibronectin. Lab Invest (1989) 1.28
Inhibition of bronchoconstriction in the guinea pig by a calcium channel blocker, nifedipine. Am Rev Respir Dis (1982) 1.27
An unusual outbreak of windborne coccidioidomycosis. N Engl J Med (1979) 1.27
Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (1994) 1.27
Mast cell activation enhances airway responsiveness to methacholine in the mouse. J Clin Invest (1993) 1.26
Defective jejunal and colonic salt absorption and alteredNa(+)/H (+) exchanger 3 (NHE3) activity in NHE regulatory factor 1 (NHERF1) adaptor protein-deficient mice. Pflugers Arch (2008) 1.26
Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Am J Respir Crit Care Med (1996) 1.25
Differential modulation of vascular cell integrin and extracellular matrix expression in vitro by TGF-beta 1 correlates with reciprocal effects on cell migration. J Cell Physiol (1992) 1.24
Bacteriology of the lower respiratory tract as determined by fiber-optic bronchoscopy and transtracheal aspiration. J Infect Dis (1976) 1.23
Atropine modification of the pulmonary effects of chemical mediators in the guinea pig. J Appl Physiol (1975) 1.23
Clinical predictors of health-related quality of life depend on asthma severity. Am J Respir Crit Care Med (2001) 1.23
Hemodynamic changes associated with obstructive sleep apnea followed by arousal in a porcine model. J Appl Physiol (1985) (1993) 1.22
Treating mild asthma--when are inhaled steroids indicated? N Engl J Med (1994) 1.22
Sponsorship, authorship, and accountability. JAMA (2001) 1.22
Expired nitric oxide after bronchoprovocation and repeated spirometry in patients with asthma. Am J Respir Crit Care Med (1998) 1.22
Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. Am Rev Respir Dis (1987) 1.22
H2 receptor mediated inhibition of immediate type hypersensitivity reactions in vivo. Am Rev Respir Dis (1978) 1.22
Airway constriction in normal humans produced by inhalation of leukotriene D. Potency, time course, and effect of aspirin therapy. JAMA (1983) 1.21
Inflammatory cell distribution within and along asthmatic airways. Am J Respir Crit Care Med (1998) 1.19
Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol (2001) 1.18
Pulmonary response to antigen infusion in the sensitized guinea pig: modification by atropine. J Appl Physiol (1975) 1.17
Enhanced 5-lipoxygenase activity in lung macrophages compared to monocytes from normal subjects. J Immunol (1987) 1.17
Exhaled nitric oxide in patients with asthma: association with NOS1 genotype. Am J Respir Crit Care Med (2000) 1.16
Peptidase modulation of the pulmonary effects of tachykinins in tracheal superfused guinea pig lungs. J Clin Invest (1990) 1.15